NASDAQ · Biotechnology · USD

Tevogen Bio Holdings Inc. (TVGN) Stock Analysis

Tevogen Bio Holdings Inc. (TVGN) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

TVGN

$7.34

+$0.17 (+2.37%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare TVGN with… →

TVGN Key Statistics

As of Sep 4, 2026

Trading

Open: $7.12
Previous Close: $7.17
Day's Range: 6.94–7.34
52-Week Range: 3.64–49.50
Volume: 2.00K
Beta: 0.19

Valuation

Market Cap: $47.79M
P/E Ratio: unprofitable
EPS (ttm): −6.29

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$26.28M
Profit margin: 0.00%
Shares Outstanding: 6.51M
1-Year Return: −83.30%

Dividend and dates

Earnings Date: November 13, 2026estimated
Avg Volume: 15.38K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

TVGN Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

+3.95%+7.74%−90.75%−67.86%−55.65%

20222023202420252026*

Year	Return
2026 (partial year)	−55.65%
2025	−67.86%
2024	−90.75%
2023	+7.74%
2022	+3.95%

As of September 4, 2026.

TVGN Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$26.28M	—
2024	$0.00	−$13.73M	—
2023	$0.00	−$60.48M	—
2022	$0.00	$4.41M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$26.14M	−$26.28M	—
2024	$0.00	—	−$53.56M	−$13.73M	—
2023	$0.00	—	−$8.84M	−$60.48M	—
2022	$0.00	—	−$953.08K	$4.41M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

TVGN Valuation vs Biotechnology Median

Median of 656 stocks

Metric	TVGN	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

Tevogen Bio Holdings Inc. (TVGN) is capitalised at $47.79M on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 18.

Over the past 52 weeks the price has ranged from $3.64 to $49.50. TVGN last closed at $7.34 on September 4, 2026. That is +$0.17 (+2.37%) against the previous close. The latest close sits 101.87% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $0.00. The same year closed with a net loss of $26.28M. Profit margin runs at 0%. Trailing earnings per share are −6.29.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

Beta against the wider market is reported at 0.19. Annualized volatility over the trailing 4 years is 153.78%. The trailing one-year price return is −83.30%. Measured over 3 years, that is −76.11% a year compounded.

Growth & Income

No dividend is on file for TVGN.

2026 is still running; the price is −55.65% year to date. Across the complete calendar years on file, 2023 returned +7.74% and 2024 returned −90.75%. Of the 4 complete calendar years on file, 2 finished higher.

Peer Comparison

Tevogen Bio Holdings Inc. (TVGN) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
Tevogen Bio Holdings Inc.	TVGN	$47.79M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. Tevogen Bio Holdings Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About Tevogen Bio Holdings Inc.

Tevogen Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in Phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920, a preclinical trial drug for treating cervical cancer; TVGN 960, a preclinical trial drug for treating oropharyngeal cancer; TVGN 601, a preclinical trial drug for treating multiple sclerosis; TVGN 930, a preclinical trial drug for treating Epstein-Barr virus associated lymphomas; and TVGN 116, a product candidate targeted at hepatitis B. It also offers artificial intelligence platform for drug development. Tevogen Inc. was formerly known as Tevogen Bio Holdings Inc. and changed its name to Tevogen Inc. in July 2026. The company was incorporated in 2020 and is headquartered in Warren, New Jersey.

Visit website →